<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03028350</url>
  </required_header>
  <id_info>
    <org_study_id>CPI-IFE-006</org_study_id>
    <nct_id>NCT03028350</nct_id>
  </id_info>
  <brief_title>Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)</brief_title>
  <official_title>A Phase 2 Multicenter, Double-blind, Randomized, Placebo-Controlled Trial to Evaluate Oral Ifetroban in Subjects With Symptomatic Aspirin Exacerbated Respiratory Disease (AERD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cumberland Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cumberland Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this phase 2 study is to assess the safety and efficacy of oral ifetroban for
      the treatment of aspirin-exacerbated respiratory disease (AERD). AERD is a disease that
      involves asthma, recurring nasal polyps, and respiratory reactions to aspirin and other
      nonsteroidal anti-inflammatory drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, placebo-controlled, double-blind phase 2 trial evaluating approximately
      76 subjects with symptomatic AERD on the safety and efficacy of 8 weeks of oral ifetroban
      treatment. Eligible AERD subjects will be randomized to receive 8 weeks of either oral
      ifetroban daily or matching placebo followed by a 2-week post-treatment period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Sino-Nasal Outcome Test-22 score</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Asthma Control Questionnaire -7 score</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Nasal Symptom score</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FEV1</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PNIFR</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FeNO</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in rescue medication</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in antibiotic use</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change From Baseline in blood, urine and nasal epithelial biomarkers</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Asthma, Aspirin-Induced</condition>
  <arm_group>
    <arm_group_label>Ifetroban Oral Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral ifetroban, 200 mg daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Oral Capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifetroban Oral Capsule</intervention_name>
    <description>Subjects will be treated with oral ifetroban daily for 8 weeks</description>
    <arm_group_label>Ifetroban Oral Capsule</arm_group_label>
    <other_name>Ifetroban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Capsule</intervention_name>
    <description>Subjects will be treated with oral placebo daily for 8 weeks</description>
    <arm_group_label>Placebo Oral Capsule</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. History of physician-diagnosed asthma

          2. History of nasal polyposis

          3. History of at least two reactions to oral aspirin or other nonselective cyclooxygenase
             inhibitor with features of lower airway involvement (cough, chest tightness, wheezing,
             dyspnea), or one reaction that was life-threatening and required hospitalization, or a
             diagnosis of AERD by a physician-conducted challenge to aspirin in the last five years
             before starting treatment.

          4. Stable asthma (post-bronchodilator FEV1 of ≥ 60%, no glucocorticoid burst for at least
             two weeks prior to starting treatment, no hospitalizations or emergency room visits
             for asthma at least three months prior to starting treatment and not on a dose &gt;1000
             µg fluticasone or equivalent daily).

          5. ≥ 18 years of age

          6. Exhibit symptomatic AERD within three weeks of starting treatment by demonstrating a
             score of at least 20 on the Sino-nasal Outcome Test (SNOT) - 22.

        Exclusion Criteria:

          1. Current smoking, defined as daily tobacco smoking in the last six months and at least
             one instance of tobacco smoking in the last three months.

          2. Current pregnancy or breastfeeding

          3. Use of oral or systemic steroids (e.g. prednisone or equivalent) &gt; 20 mg daily in the
             last four weeks before starting treatment.

          4. Daily use of long-acting antihistamines in the last two weeks before starting
             treatment.

          5. Less than 12 months of allergy shots (maintenance dose of allergy shots are allowed if
             treatment duration exceeds 12 months). Less than 1 month of 5-lipoxygenase inhibitors
             (e.g. zileuton) and/or leukotriene receptor antagonists (e.g. montelukast).

          6. Any use of nonsteroidal anti-inflammatory drugs (NSAIDs) or any drug that inhibits the
             cyclooxygenase enzyme in the last two weeks before starting treatment.

          7. History of bleeding diathesis or use of anticoagulant or antiplatelet drugs in the
             last two weeks before starting treatment.

          8. Any immunosuppressive treatment including but not limited to methotrexate,
             cyclosporine, mycophenolate, tacrolimus, gold, penicillamine, sulfasalazine,
             hydroxychloroquine, azathioprine, and cyclophosphamide in the last two weeks before
             starting treatment (maintenance dose of allergy shots are allowed if treatment
             duration exceeds 12 months). Biologics/immunotherapies such as Xolair or Nucala are
             permitted if duration exceeds three months.

          9. Endoscopic sinus surgery / polypectomy within the past three months

         10. Previously treated in a clinical trial with ifetroban within the past three months.

         11. Previously treated with other investigational drugs within eight weeks or five
             half-lives, whichever is longer, before screening

         12. Conditions/concomitant disease which make them unevaluable for the efficacy endpoints
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew White, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scripps Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Byron Kaelin, RN, BSHS</last_name>
    <phone>615-255-0068</phone>
    <phone_ext>250</phone_ext>
    <email>bkaelin@cumberlandpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ines Macias-Perez, PhD</last_name>
    <phone>615-979-5778</phone>
    <email>imaciasperez@cumberlandpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Scripps Clinic - Carmel Valley</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Giovanetty</last_name>
      <phone>858-764-3023</phone>
    </contact>
    <investigator>
      <last_name>Andrew White, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aakanksha Rathor, MD</last_name>
      <phone>408-872-2257</phone>
    </contact>
    <investigator>
      <last_name>Peter Hwang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Research Center</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laine Batista</last_name>
      <phone>305-603-8844</phone>
    </contact>
    <contact_backup>
      <last_name>Damian Beltran-Garces</last_name>
      <phone>(305) 603-8844</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Kansas City Allergy and Asthma Associates, PA</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James B Sterner, MD</last_name>
      <phone>913-338-1610</phone>
    </contact>
    <contact_backup>
      <last_name>Andrea Bennington, CCRC</last_name>
      <phone>913-338-1610</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mydalyn Beronilla, MPH</last_name>
      <phone>929-263-3262</phone>
    </contact>
    <investigator>
      <last_name>Elina Jerschow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Trials , LLC</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nashat Gabrail, MD</last_name>
      <phone>330-492-3345</phone>
    </contact>
    <contact_backup>
      <last_name>Hannah Crocker</last_name>
      <phone>330-492-3345</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John V Bosso, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Laurel Doghramji, BSN</last_name>
      <phone>215-615-1643</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Dorminy, MEd, LPN</last_name>
      <phone>615-936-8384</phone>
    </contact>
    <investigator>
      <last_name>Rakesh Chandra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Martin</last_name>
      <phone>214-648-3626</phone>
    </contact>
    <investigator>
      <last_name>David Khan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Medical Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B.J. Ferrebee Ghamandi, MHA</last_name>
      <phone>434-243-1558</phone>
    </contact>
    <investigator>
      <last_name>Spencer Payne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2017</study_first_submitted>
  <study_first_submitted_qc>January 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2017</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
    <mesh_term>Asthma, Aspirin-Induced</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ifetroban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

